News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Invitrogen Corporation (IVGN) and Chroma Therapeutics Extend Kinase Screening Partnership


2/25/2008 8:47:43 AM

CARLSBAD, Calif. & ABINGDON, England--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced an extension to its partnership with Chroma Therapeutics Ltd. As a part of this partnership, Invitrogen will use its SelectScreen™ platform to perform biochemical screening on Chroma’s multi-targeted kinase inhibitors at Invitrogen’s Paisley, Scotland, UK, facility. Financial details of the collaboration were not disclosed.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES